C6461008, Study to Evaluate Safety & efficacy of PF-08634404 in adults with RCC

• Research type

  Research Study

• Full title

  AN INTERVENTIONAL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA

• IRAS ID

  1013128

• Contact name

  Noel Landsman

• Contact email

  Noel.Landsman@pfizer.com

• Sponsor organisation

  Pfizer Inc.

• Clinicaltrials.gov Identifier

  NCT07227415

• Research summary

  This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other parts of the body). The study will look at the safety of the study medicine, when given alone or with other anticancer medicines, and how this type of cancer responds to them.
  To join the study, participants must be adults; with locally advanced or metastatic RCC; who have not received treatment for their advanced kidney cancer.
  Participants will receive study medicine either alone or with other anticancer medicines. The medicine will be given through intravenous (IV) infusions, which means it will be injected directly into a vein. All treatments will take place at clinical study sites, where trained medical staff will take care of participants during and after each visit.

• REC name

  East of England - Cambridge Central Research Ethics Committee

• REC reference

  26/EE/0009

• Date of REC Opinion

  25 Mar 2026

• REC opinion

  Further Information Unfavourable Opinion